Alternative testing systems for evaluating noncarcinogenic, hematologic toxicity

Environmental Health Perspectives

Volumn 106, Issue SUPPL. 2, 1998, Pages 541-557

  Parchment, Ralph E ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

CFU GM; Hematopoiesis; Hematotoxicity; Hematotoxicology; In vitro assay; IND; MTD; Myelosuppression; Myelotoxicity; NDA; Neutropenia; NOAEL; Permissible exposure limit; Progenitor cells; Stem cells; Thrombocytopenia; Toxicology

Indexed keywords

BLOOD CELL COUNT; BLOOD TOXICITY; BONE MARROW; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CELL LINEAGE; CHEMICAL STRUCTURE; COLONY FORMING UNIT GM; CONFERENCE PAPER; DOSE RESPONSE; HEMATOPOIETIC TISSUE; MUCOSA INFLAMMATION; NEUTROPENIA; NEUTROPHIL; PREDICTION; PRIORITY JOURNAL; SPECIES DIFFERENCE; STEM CELL; THROMBOCYTOPENIA;

EID: 0031860762     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.98106541     Document Type: Conference Paper

References (219)

1. Gribaldo L, Bueren J, Deldar A, Hokland P, Meredith C, Moneta D, Monesso P, Parchment R, Parent-Massin D, Pessina A et al. The use of in vitro systems for evaluating hematotoxicity. ATLA 24:211-231 (1996).
2. Wu AM, Siminovitch L, Till JE, McCulloch EA. Evidence for a relationship between mouse hemopoietic stem cells and cells forming colonies in culture. Proc Natl Acad Sci USA 59:1209-1215 (1968).
3. Dexter TM, Allen TD, Lajtha LG. Conditions controlling the proliferation of haemopoietic stem cells in vitro. J Cell Physiol 91:335-344 (1977).
4. Till JE, Price GB, Mak TW, McCulloch EA. Regulation of blood cell differentiation. Fed Proc 34:2279-2284 (1975).
5. Pluznik DH, Sachs L. The cloning of normal "mast" cells in tissue culture. J Cell Comp Physiol 66:319-324 (1965).
6. Bradley TR, Metcalf D. The growth of mouse bone marrow cells in vitro. Aust J Exp Biol Med Sci 44:287-299 (1966).
7. Ichikawa Y, Pluznik DH, Sachs L. In vitro control of the development of macrophage and granulocyte colonies. Proc Natl Acad Sci USA 56:488-495 (1966).
8. Stephenson JR, Axelrad AA, McLeod DI, Schreeve MM. Induction of colonies of hemoglobin-synthesizing cells by erythropoietin in vitro. Proc Natl Acad Sci USA 68:1542-1546 (1971).
9. Iscove NN, Sieber F. Erythroid progenitors in mouse bone marrow detected by macroscopic colony formation in culture. Exp Hematol 3:32-43 (1975).
10. Hara H, Ogawa M. Erthropoietic precursors in mice with phenylhydrazine-induced anemia. Am J Hematol 1:453-458 (1975).
11. Gregory CJ, Eaves AC. Human marrow cells capable of erythropoietic differentiation in vitro:definition of three erythroid colony responses. Blood 49:855-864 (1977).
12. Clarke BJ, Housman D. Characterization of an erythroid precursor cell of high proliferative capacity in normal human peripheral blood. Proc Natl Acad Sci USA 74:1105-1109 (1977).
13. Johnson GR, Metcalf D. Nature of cells forming erythroid colonies in agar after stimulation by spleen conditioned medium. J Cell Physiol 94:243-252 (1978).
14. Koury MJ, Kost TA, Hankins WD, Krantz SB. Response of erythroid day 3 burst-forming units to endotoxin and erythropoietin. Proc Soc Exp Biol Med 162:275-280 (1979).
15. Eliason JF, Van Zant G, Goldwasser E. The relationship of hemoglobin synthesis to erythroid colony and burst formation. Blood 53:935-945 (1979).
16. Wagemaker G, Peters MF, Bol SJ. Induction of erythropoietin responsiveness in vitro by a distinct population of bone marrow cells. Cell Tissue Kinet 12:521-537 (1979).
17. Meytes D, Ortega JA, Shore NA, Dukes PP. Human erythroid burst-promoting activity produced by phytohemagglutinin-stimulated, radioresistant peripheral blood mononuclear cells. Blood 54:1050-1057 (1979).
18. Nathan DG, Chess L, Hillman DG, Clarke B, Breard J, Merler E, Housman DE. Human erythroid burst-forming unit:T-cell requirement for proliferation in vitro. J Exp Med 147:324-339 (1978).
19. Sonoda Y, Maekawa T, Kuzuyama Y, Clark SC, Abe T. Human interleukin-9 supports formation of a subpopulation of erythroid bursts that are responsive to interleukin-3. Am J Hematol 41:84-91 (1992).
20. Metcalf D, MacDonald HR, Odartchenko N, Sordat B. Growth of mouse megakaryocyte colonies in vitro, Proc Natl Acad Sci USA 72:1744-1748 (1975).
21. Nakeff A, Daniels-McQueen S. In vitro colony assay for a new class of megakaryocyte precursor:colony-forming unit megakaryocyte (CFU-M). Proc Soc Exp Biol Med 151:587-590 (1976).
22. Vainchenker W, Bouguet J, Guichard J, Breton-Gorius J. Megakaryocyte colony formation from human bone marrow precursors. Blood 54:940-945 (1979).
23. Williams N, Jackson H, Sheridan AP, Murphy MJ Jr, Elste A, Moore MA. Regulation of megakaryopoiesis in long-term murine bone marrow cultures. Blood 51:245-255 (1978).
24. Mei RL, Burstein SA. Megakaryocytic maturation in murine long-term bone marrow culture:role of interleukin-6. Blood 78:1438-1447 (1991).
25. Erickson-Miller CL, Ji H, Parchment RE, Murphy MJ Jr. Megakaryocyte colony-stimulating factor (Meg-CSF) is a unique cytokine specific for the megakaryocyte lineage. Br J Haematol 84:197-203 (1993).
26. Ogata K, Erickson-Miller CL, Nomura T, Abe K, Zhang Z, Murphy MJ Jr. Effects of recombinant cytokines on murine megakaryocyte colony formation in a serum-free fibrin clot culture system. Pathobiology 60:143-148 (1992).
27. Kaushansky K, Lok S, Holly RD, Broudy VC, Lin N, Bailey MC, Forstrom JW, Buddle MM, Oort PJ, Hagen FS et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-mpl ligand thrombopoietin. Nature 369:568-571 (1994).
28. Kaushansky K. The mpl ligand:molecular and cellular biology of the critical regulator of megakaryocyte development. Stem Cells (Dayt) 12(Suppl 1):91-96 (1994).
29. Broudy VC, Lin NL, Kaushansky K. Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood 85:1719-1726 (1995).
30. Methia N, Louache F, Vainchenker W, Wendling F. Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood 82:1395-1401 (1993).
31. Nishihira H, Toyoda Y, Miyazaki H, Kigasawa H, Ohsaki E. Growth of macroscopic human megakaryocyte colonies from cord blood in culture with recombinant human thrombopoietin (c-mpl ligand) and the effects of gestational age on frequency of colonies. Br J Haematol 92:23-28 (1996).
32. Zauli G, Vitale L, Brunelli MA, Bagnara GP. Prevalence of the primitive megakaryocyte progenitors (BFU-meg) in adult human peripheral blood. Exp Hematol 20:850-854 (1992).
33. Choi KW, Bloom AD. Cloning human lymphocytes in vitro. Nature 227:171-173 (1970).
34. Klein AK, Dyck JA, Shimizu JA, Stitzel KA, Wilson FD, Cain GR. Effect of continuous, whole-body gamma irradiation upon canine lymphohematopoietic (CFU-GM, CFU-L) progenitors and a possible hematopoietic regulatory population. Radiat Res 101:332-350 (1985).
35. Dorshkind K, Johnson A, Harrison Y, Landreth KS. A colony assay system that detects B cell progenitors in fresh and cultured bone marrow. J Immunol Methods 123:93-101 (1989).
36. Johnson GR, Metcalf D. Pure and mixed erythroid colony formation in vitro stimulated by spleen conditioned medium with no detectable erythropoietin. Proc Natl Acad Sci USA 74:3879-3882 (1997).
37. Metcalf D, Johnson GR, Mandel TE. Colony formation in agar by multipotential hemopoietic cells. J Cell Physiol 98:401-420 (1979).
38. Williams N, Jackson H, Meyers P. Isolation of pluriporent hemopoietic stem cells and clonable precursor cells of erythrocytes, granulocytes, macrophages and megakaryocytes from mouse bone marrow. Exp Hematol 7:524-534 (1979).
39. Johnson GR. Colony formation in agar by adult bone marrow multipotential hemopoietic cells. J Cell Physiol 103:371-383 (1980).
40. Nishi N, Nakahata T, Koike K, Takagi M, Naganuma K, Akabane T. Induction of mixed erythroid-megakaryocyte colonies and bipotential blast cell colonies by recombinant human erythropoietin in serum-free culture. Blood 76:1330-1335 (1990).
41. Hara H, Ogawa M. Murine hemopoietic colonies in culture containing normoblasts, macrophages, and megakaryocytes. Am J Hematol 4:23-34 (1978).
42. Fauser AA, Messner HA. Identification of megakaryocytes, macrophages, and eosinophils in colonies of human bone marrow containing neutrophilic granulocytes and erythroblasts. Blood 53:1023-1027 (1979).
43. Bradley TR, Hodgson GS. Detection of primitive macrophage progenitor cells in mouse bone marrow. Blood 54:1446-1450 (1979).
44. Baines P, Bol S, Rosendaal M. Characterization of a developmentally early macrophage progenitor found in normal mouse marrow. Br J Haematol 48:147-153 (1981).
45. Baines P, Lajmanovich A, Hollard D. Enrichment of high proliferation potential colony forming cells from mouse marrow by selecting low-density cells expressing receptors for wheat germ agglutinin. Leuk Res 8:853-861 (1984).
46. Hodgson GS, Bradley TR, Radley JM. The organization of hemopoietic tissue as inferred from the effects of 5-fluorouracil. Exp Hematol 10:26-35 (1982).
47. Boswell HS, Wade PM Jr, Quesenberry PJ. Thy-1 antigen expression by murine high-proliferative capacity hematopoietic progenitor cells. I:Relation between sensitivity to depletion by Thy-1 antibody and stem cell generation potential. J Immunol 133:2940-2949 (1984).
48. Leary AG, Ogawa M. Blast cell colony assay for umbilical cord blood and adult bone marrow progenitors. Blood 69:953-956 (1987).
49. McNiece IK, Stewart FM, Deacon DM, Temeles DS, Zsebo KM, Clark SC, Quesenberry PJ. Detection of a human CFC with a high proliferative potential. Blood 74:609-612 (1989).
50. McNiece IK, Bertoncello I, Kriegler AB, Quesenberry PJ. Colony-forming cells with high proliferative potential (HPP-CFC). Int J Cell Cloning 8:146-160 (1990).
51. Ploemacher RE, van der Sluijs JP, Voerman JS, Brons NH. An in vitro limiting-dilution assay of long-term repopulating hematopoietic stem cells in the mouse. Blood 74:2755-2763 (1989).
52. Sutherland HJ, Lansdorp PM, Henkelman DH, Eaves AC, Eaves CJ. Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers. Proc Natl Acad Sci USA 87:3584-3588 (1990).
53. Pettengell R, Luft T, Henschler R, Hows JM, Dexter TM, Ryder D, Testa NG. Direct comparison by limiting dilution analysis of long-term culture-initiating cells in human bone marrow, umbilical cord blood, and blood stem cells. Blood 84:3653-3659 (1994).
54. Breems DA, Blokland EA, Neben S, Ploemacher RE. Frequency analysis of human primitive haematopoietic stem cell subsets using a cobblestone area forming cell assay. Leukemia 8:1095-1104 (1994).
55. Eaves CJ, Sutherland HJ, Udomsakdi C, Lansdorp PM, Szilvassy SJ, Fraser CC, Humphries RK, Barnett MJ, Phillips GL, Eaves AC. The human hematopoietic stem cell in vitro and in vivo. Blood Cells 18:301-307 (1992).
56. Lemieux ME, Rebel VI, Lansdorp PM, Eaves CJ. Characterization and purification of a primitive hematopoietic cell type in adult mouse marrow capable of lymphomyeloid differentiation in long-term marrow switch cultures. Blood 86:1339-1347 (1995).
57. Ploemacher RE, Brons RH. Separation of CFU-S from primitive cells responsible for reconstitution of the bone marrow hemopoietic stem cell compartment following irradiation:evidence for a pre-CFU-S cell. Exp Hematol 17:263-266 (1989).
58. Murray L, DiGiusto D, Chen B, Chen S, Combs J, Conti A, Galy A, Negrin R, Tricot G, Tsukamoto A. Analysis of human hematopoietic stem cell populations. Blood Cells 20:364-369 (1994).
59. Orlic D, Fischer R, Nishikawa S, Nienhuis AW, Bodine DM. Purification and characterization of heterogeneous pluripotent hematopoietic stem cell populations expressing high levels of c-kit receptor. Blood 82:762-770 (1993).
60. Orlic D, Anderson S, Bodine DM. Biological properties of sub-populations of pluripotent hematopoietic stem cells enriched by elutriation and flow cytometry. Blood Cells 20:107-117 (1994).
61. Watt SM, Visser JW. Recent advances in the growth and isolation of primitive human haemopoietic progenitor cells. Cell Prolif 25:263-297 (1992).
62. Ziilmans JM, Visser JW, Kleiverda K, Kluin PM, Willemze R, Fibbe WE. Modification of rhodamine staining allows identification of hematopoietic stem cells with preferential short-term or long-term bone marrow-repopulating ability. Proc Natl Acad Sci USA 92:8901-8905 (1995).
63. Berardi AC, Wang A, Levine JD, Lopez P, Scadden DT. Functional isolation and characterization of human hematopoietic stem cells. Science 267:104-108 (1995).
64. Bungart B, Loeffler M, Goris H, Dontje B, Diehl V, Nijhof W. Differential effects of recombinant human colony stimulating factor (rh G-CSF) on stem cells in marrow, spleen and peripheral blood in mice. Br J Haematol 76:174-179 (1990).
65. Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 17:331-340 (1974).
66. Van Den Heuvel R, Schoeters G, Leppens H, Vanderborght O. Stromal cells in long-term cultures of liver, spleen, and bone marrow at different developmental ages have different capacities to maintain GM-CFC proliferation. Exp Hematol 19:115-121 (1991).
67. Aizawa S, Yaguchi M, Nakano M, Toyama K, Inokuchi S, Imai T, Yasuda M, Nabeshima R, Handa H. Hematopoietic supportive function of human bone marrow stromal cell lines established by a recombinant SV40-adenovirus vector. Exp Hematol 22:482-487 (1994).
68. Friedenstein AJ, Deriglasova UF, Kulagina NN, Panasuk AF, Rudakowa SF, Luria EA, Ruadkow IA. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol 2:83-92 (1974).
69. Dexter TM. Haemopoiesis in long-term bone marrow cultures. A review. Acta Haematol 62:299-305 (1979).
70. Gartner S, Kaplan HS. Long-term culture of human bone marrow cells. Proc Natl Acad Sci USA 77:4756-4759 (1980).
71. Johnson A, Dorshkind K. Stromal cells in myeloid and lymphoid lone-term bone marrow cultures can support multiple hemopoietic lineages and modulate their production of hemopoietic growth factors. Blood 68:1348-1354 (1986).
72. Wang TY, Brennan JK, Wu JH. Multilineal hematopoiesis in a three-dimensional murine long-term bone marrow culture. Exp Hematol 23:26-32 (1995).
73. Whitlock CA, Witte ON. Long-term culture of B lymphocytes and their precursors from murine bone marrow. Proc Natl Acad Sci USA 79:3608-3612 (1982).
74. Nagasawa R, Kanagawa O, Tittle TV, Chiller JM. In vivo maturation of pre-B cells derived from long-term cultured bone marrow. J Immunol 135:965-972 (1985).
75. Whitlock CA, Witte ON. Long-term culture of murine bone marrow precursors of B lymphocytes. Methods Enzymol 150:275-286 (1987).
76. Dorshkind K. In vitro differentiation of B lymphocytes from primitive hemopoietic precursors present in long-term bone marrow cultures. J Immunol 136:422-429 (1986).
77. Collins LS, Dorshkind K. A stromal cell line from myeloid long-term bone marrow cultures can support myelopoiesis and B lymphopoiesis. J Immunol 138:1082-1087 (1987).
78. Greenberg PL, Schrier SL. Clinical utility of in vitro evaluation of granulopoiesis. Annu Rev Med 25:269-278 (1974).
79. Marsh JC. Chemical toxicity of the granulocyte. Environ Health Perspect 39:71-78 (1981).
80. Boorman GA, Luster MI, Dean JH, Campbell ML. Assessment of myelotoxicity caused by environmental chemicals. Environ Health Perspect 43:129-135 (1982).
81. Deldar A, Lewis H, Bloom J, Weiss L. Reproducible cloning assays for in vitro growth of canine hematopoietic progenitor cells and their potential applications in investigative hematotoxicity. Am J Vet Res 49:1393-1401 (1988).
82. Naughton BA, Sibanda B, Azar L, San Roman J. Differential effects of drugs upon hematopoiesis can be assessed in longterm bone marrow cultures established on nylon screens. Proc Soc Exp Biol Med 199:481-490 (1992).
83. Noble C, Sina JF. Usefulness of the in vitro bone marrow colony-forming assay in cellular toxicology. In Vitro Toxicol 6:187-195 (1993).
84. Parchment RE, Huang M, Erickson-Miller CL. Roles for in vitro myelotoxicity tests in preclinical drug development and clinical trial planning. Toxicol Pathol 21:241-250 (1993).
85. Deldar A, Stevens CE. Development and application of in vitro models of hematopoiesis to drug development. Toxicol Pathol 21:231-240 (1993).
86. Deldar A. Drug-induced blood disorders:review of pathogenetic mechanisms and utilisation of bone marrow cell culture technology as an investigative approach. Curr Top Vet Res 1:83-101 (1994).
87. Deldar A, Parchment RE. Preclinical risk assessment for hematotoxicity:animal models and in vitro systems. In:Comprehensive Toxicology (Sipes GI, McQueen CA, Gandolfi AJ, eds). Vol 4:Toxicology of the Hematopoietic System (Bloom JC, ed). New York:Pergamon, 1997;303-320.
88. Parchment RE, Murphy MJ Jr. Human hematopoietic stem cells:laboratory assessment and response to toxic injury. In:Comprehensive Toxicology (Sipes GI, McQueen CA, Gandolfi AJ, eds). Vol 4:Toxicology of the Hematopoietic System (Bloom JC, ed). New York:Pergamon, 1997;335-362.
89. Treleaven J, Barrett J. Drugs and the bone marrow. Br J Hosp Med 44:245-250 (1990).
90. Greenberger JS. Toxic effects on the hematopoietic microenvironment. Exp Hematol 19:1101-1109 (1991).
91. Young GA, Croaker G, Vincent PC, Forrest P, Morris TC. The CFU-C assay in patients with neutropenia and, in particular, drug associated neutropenia. Clin Lab Haematol 9:245-253 (1987).
92. Naughton BA, San Roman J, Sibanda B, Weintraub JP, Kamali V. Stereotypic culture systems for liver and bone marrow:evidence for the development of cuntional tissue in vitro and following implantation in vivo. Biotechnol Bioeng 43:810-825 (1994).
93. Bloom JC. Introduction to hematotoxicology. In:Comprehensive Toxicology (Sipes GI, McQueen CA, Gandolfi AJ, eds). Vol 4:Toxicology of the Hematopoietic System (Bloom JC, ed). New York:Pergamon, 1997;1-10.
94. Levitt LJ, Quesenberry PJ. The effect of lithium on murine hematopoiesis in a liquid culture system. N Engl J Med 302:713-719 (1980).
95. Chatelain C, Burstein SA, Harker LA. Lithium enhancement of megakaryocytopoiesis in culture:mediation via accessory marrow cells. Blood 62:172-176 (1983).
96. Boggs DR, Joyce RA. The hematopoietic effects of lithium. Semin Hematol 20:129-138 (1983).
97. Silberstein DS, Austen KF, Owen WF Jr. Hemopoietins for eosinophils. Glycoprotein hormones that regulate the development of inflammation in eosinophilia-associated disease. Hematol Oncol Clin North Am 3:511-533 (1989).
98. Owen WF Jr, Petersen J, Sheff DM, Folkerth RD, Anderson RJ, Corson JM, Sheffer AL, Austen KF. Hypodense eosinophils and interleukin 5 activity in the blood of patients with the eosinophilia-myalgia syndrome. Proc Natl Acad Sci USA 87:8647-8651 (1990).
99. Yamaoka KA, Miyasaka N, Inuo G, Saito I, Kolb JP, Fujita K, Kashiwazaki S. 1,1′-Ethylidenebis(tryptophan) (Peak E) induces functional activation of human eosinophils and interleukin 5 production from T lymphocytes:association of eosinophilia-myalgia syndrome with a L-tryptophan contaminant. J Clin Immunol 14:50-60 (1994).
100. Gallamini A, Carbone A, Lista P, Cavallero G, Reato G, Fruttero A, Novero D, Asnaghi G, di Celle PF, Foa R. Intestinal T-cell lymphoma with massive tissue and blood eosinophilia mediated by IL-5. Leuk Lymphoma 17:155-161 (1995).
101. Macdonald D, Gordon AA, Kajitani H, Enokihara H, Barrett AJ. Interleukin-2 treatment-associated eosinophilia is mediated by interleukin-5 production. Br J Haematol 76:168-173 (1990).
102. Dale DC, Fauci AS, Guerry D IV, Wolff SM. Comparison of agents producing a neutrophilic leukocytosis in man:nydrocortisone, prednisone, endotoxin, and etiocholanolone. J Clin Invest 56:808-813 (1975).
103. Grillot-Courvalin C, Vinci G, Tsapis A, Dokhelar MC, Vainchenker W, Brouet JC. The syndrome of T8 hyperlymphocytosis:variation in phenotype and cytotoxic activities of granular cells and evaluation of their role in associated neutropenia. Blood 69:1204-1210 (1987).
104. van der Veen JP, Goldschmeding R, Miedema F, Smit JW, Melief CJ, von dem Borne AE. K-cell lymphocytosis/neutropenia syndrome:the neutropenia is not caused by autoimmunity. Br J Haematol 64:777-787 (1986).
105. Smith JG, Smith MA, James I, Blundell E, Maddison PJ. Inhibition of CFU-GM by prostaglandins in a case of chronic T-cell lymphocytosis and neutropenia. Br J Haematol 73:148-151 (1989).
106. Greenberg P, Bax I, Mara B, Schrier S. Alterations of granulopoiesis following chemotherapy. Blood 44:375-383 (1974).
107. Bruce WR, Meeker BE, Valeriote FA. Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo. J Natl Cancer Inst 37:233-245 (1966).
108. Valeriote F, van Putten L. Proliferation-dependent cytotoxicity of anticancer agents:a review. Cancer Res 35:2619-2630 (1975).
109. Gallini R, Hendry JH, Molineux G, Testa NG. The effect of low dose rate on recovery of hemopoietic and stromal progenitor cells in gamma-irradiated mouse bone marrow. Radiat Res 115:481-487 (1988).
110. Horikoshi A, Murphy MJ Jr. Comparative effects of chemotherapeutic drugs on human and marine hematopoietic progenitors in vitro. Chemotherapy 28:480-501 (1982).
111. Qi DY, Hendry JH, Testa NG. Interactions in recovery and in residual injury from sequential treatments of mouse haemopoietic and stromal marrow cell populations, using X-rays, cyclophosphamide and busulphan. Radiother Oncol 20:46-52 (1991).
112. Seed TM, Kaspar LV. Changing patterns of radiosensitivity of hematopoietic progenitors from chronically irradiated dogs prone either to aplastic anemia or to myeloproliferative disease. Leuk Res 14:299-307 (1990).
113. Pessina A, Neri MG, Muschiato A, Raimondi A. Inhibition of granulocytic-macrophagic precursor cells (CFU-C) by heatlabile enterotoxin (LT) produced by Escherichia coli. Biomed Pharmacother 37:447-452 (1983).
114. Parent-Massin D, Thouvenot D. In vitro study of pesticide hematotoxicity in human and rat progenitors. J Pharmacol Toxicol Methods 30:203-207 (1993).
115. Parent-Massin D, Fuselier R, Thouvenot D. In vitro toxicity of trichothecenes on human haematopoietic progenitors. Food Addit Contam 11:441-447 (1994).
116. Inoue T, Tsushita K, Itoh T, Ogura M, Hotta T, Saneyoshi M, Yoshida S, Saitoh H, Tomoda Y, Nagai Y. In vitro bone marrow toxicity of nucleoside analogs against human immunodeficiency virus. Antimicrob Agents Chemother 33:576-579 (1989).
117. Fink FM, Maurer-Dengg K, Fritsch G, Mann G, Zoubek A, Falk M, Gadner H. Recombinant human granulocyte-macrophage colony-stimulating factor in septic neucropenic pediatric cancer patients:detection of circulating hematopoietic precursor cells correlates with rapid granulocyte recovery. Med Pediatr Oncol 25:365-371 (1995).
118. Wittels B. Bone marrow biopsy changes following chemotherapy for acute leukemia. Am J Surg Pathol 4:35-142 (1980).
119. Schurig JE, Schlein A, Florczyk AP, Farwell AR, Bradner WT. Animal models for evaluating the myelosuppressive effects of cancer chemotherapeutic agents. Exp Hematol 13(Suppl 16):101-105 (1985).
120. Ventura GJ, Reading CL, Hester JP, Vadhan-Raj S. Circulating myeloid progenitor cell kinetics during hematologic recovery from chemotherapy and subsequent recombinant human granulocyte-macrophage colony-stimulating factor administration. Acta Haematol 84:175-181 (1990).
121. Ema H, Suda T, Sakamoto S, Tomonaga T, Tsunoda J, Muroi K, Komatsu N, Miwa A, Ohsaka A, Yoshida M et al. Effects of the in vivo administration of recombinant human granulocyte colony-stimulating factor following cytotoxic chemotherapy on granulocytic precursors in patients with malignant lymphoma. Jpn J Cancer Res 80:577-582 (1989).
122. Ponassi A, Morra L, Mela GS, Caristo G, Parodi GB, Sacchetti C. Correlation between blood granulocyte progenitor cells and polymorphonuclear leukocytes. A tentative pathophysiological subgrouping of neutropenic and neutrophilic patients. Biomed Pharmacother 37:293-297 (1983).
123. Mukai J, Shimizu E, Ogura T. Granulocyte-colony-stimulating factor enhances the circulating hematopoietic progenitors in lung cancer patients treated with cisplatin-containing regimens. Jpn J Cancer Res 83:746-753 (1992).
124. Neelis KJ, Dubbelman YD, Luo QL, Thomas GR, Eaton DL, Wagemaker G. Simultaneous administration of TPO and G-CSF after cytoreductive treatment of rhesus monkeys prevents thrombocytopenia, accelerates platelet and red cell reconstitution, alleviates neutropenia, and promotes the recovery of immature bone marrow cells. Exp Hematol 25:1084-1093 (1997).
125. Du DL, Volpe DA, Grieshaber CK, Murphy MJ Jr. Comparative toxicity of fostriecin, hepsulfam and pyrazine diazohydroxide to human and murine hematopoietic progenitor cells in vitro. Invest New Drugs 9:149-157 (1991).
126. Hendricks CB, Grochow LB, Rowinsky EK, Forastiere AA, McGuire WP, Ettinger DS, Sartorius S, Lubejko B, Donehower RC. Phase I and pharmacokinetic study of hepsulfam (NSC 329680). Cancer Res 51:5781-5785 (1991).
127. Volpe DA, Du DL, Zurlo MG, Mongelli N, Murphy MJ Jr. Comparative in vitro myelotoxicity of FCE 24517, a distamycin derivative, to human, canine and murine hematopoietic progenitor cells. Invest New Drugs 10:255-261 (1992).
128. Volpe DA, Du DL, Grieshaber CK, Murphy MJ Jr. In vitro characterization of the myelotoxicity of cyclopentenyl cytosine. Cancer Chemother Pharmacol 34:103-108 (1994).
129. Parchment RE, Volpe DA, LoRusso PM, Erickson-Miller CL, Murphy MJ Jr, Grieshaber CK. In vivo-in vitro correlation of myelotoxicity of 9-methoxypyrazoloacridine (NSC-366140, PD115934) to myeloid and erythroid hematopoietic progenitors from human, murine, and canine marrow. J Natl Cancer Inst 86:273-280 (1994).
130. Volpe DA, Cole K, Sandeen MA, Kohn EC. In vitro and in vivo myelotoxicity of CAI to human and murine hematopoietic progenitor cells. Am J Hematol 50:277-282 (1995).
131. Du DL, Volpe DA, Grieshaber CK, Murphy MJ Jr. Effects of L-phenylalanine mustard and L-buthionine sulfoximine on murine and human hematopoietic progenitor cells in vitro. Cancer Res 50:4038-4043 (1990).
132. Smith AC, Liao JT, Page JG, Wietjes MG, Grieshaber CK. Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice. Cancer Res 49:5385-5391 (1989).
133. Pressacco J, Erlichman C. Combination studies with 3′-azido-3′-deoxythymidine (AZT) plus ICI D1694. Cytotoxic and biochemical effects. Biochem Pharmacol 46:1989-1997 (1993).
134. Pressacco J, Hedley DW, Erlichman C. ICI D1694 and idoxuridine:a synergistic antitumor combination. Cancer Res 54:3772-3778 (1994).
135. Kalechman Y, Sotnik-Barkai I, Albeck M, Sredni B. Protection of bone marrow stromal cells from the toxic effects of cyclophosphamide in vivo and of ASTA-Z 7557 and etoposide in vitro by ammonium trichloro(dioxyethylene-O-O′)tellurate (AS101). Cancer Res 53:1838-1844 (1993).
136. Kalechman Y, Rushkin G, Nerubay J, Albeck M, Sredni B. Effect of the immunomodulator AS101 on chemotherapy-induced multilineage myelosuppression, thrombocytopenia, and anemia in mice. Exp Hematol 23:1358-1366 (1995).
137. Walker RE, Parker RI, Kovacs JA, Masur H, Lane HC, Carleton S, Kirk LE, Gralnick HR, Fauci AS. Anemia and erythropoiesis in patients with the acquired immunodeficiency syndrome (AIDS) and Kaposi sarcoma treated with zidovudine. Ann Intern Med 108:372-376 (1988).
138. Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Hirsch MS et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 317:192-197 (1987).
139. Dainiak N, Worthington M, Riordan MA, Kreczko S, Goldman L. 3′-Azido-3′-deoxythymidine (AZT) inhibits proliferation in vitro of human haematopoietic progenitor cells. Br J Haematol 69:299-304 (1988).
140. Morse GD, Olson J, Portmore A, Taylor C, Plank C, Reichman RC. Pharmacokinetics of orally administered zidovudine among patients with hemophilia and asymptomatic human immunodeficiency virus (HIV) infection. Antiviral Res 11:57-65 (1989).
141. Bhalla K, Birkhofer M, Grant S, Graham G. The effect of recombinant human granulocyte-macrophage colony-stimulating factor (rGM-CSF) on 3′-azido-3′-deoxythymidine (AZT)-mediated biochemical and cytotoxic effects on normal human myeloid progenitor cells. Exp Hematol 17:17-20 (1989).
142. Balis FM, Pizzo PA, Eddy J, Wilfert C, McKinney R, Scott G, Murphy RF, Jarosinski PF, Falloon J, Poplack DG. Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection. J Pediatr 114:880-884 (1989).
143. Collins JM, Unadkat JD. Clinical pharmacokinetics of zidovudine. An overview of current data. Clin Pharmacokinet 17:1-9 (1989).
144. Ganser A, Greher J, Volkers B, Staszewski S, Hoelzer D. Inhibitory effect of azidothymidine, 2′-3′-dideoxyadenosine, and 2′-3′-dideoxycytidine on in vitro growth of hematopoietic progenitor cells from normal persons and from patients with AIDS. Exp Hematol 17:321-325 (1989).
145. Du DL, Volpe DA, Grieshaber CK, Murphy MJ Jr. In vitro myelotoxicity of 2′,3′-dideoxynucleosides on human hematopoietic progenitor cells. Exp Hematol 18:832-836 (1990).
146. Irvine AE, Morris TC, Kelly GJ, McCracken N. Ticarcillin-induced neutropenia corroborated by in vitro CFU-C toxicity. Acta Haematol 70:364-368 (1983).
147. Volpe DA, Du DL, Verhoef V, Murphy MJ Jr. Myelotoxicity of rifabutin and 3′-azido-3′-deoxythymidine, alone and in combination, to human hematopoietic progenitor cells in vitro. Pathobiology 61:77-82 (1993).
148. Haworth C, Morris-Jones PH, Testa NG. Long-term bone-marrow damage in children treated for ALL:evidence from in vitro colony assays (GM-CFC and CFUF). Br J Cancer 46:918-923 (1982).
149. Jacobsen SE, Keller JR, Ruscetti FW, Kondaiah P, Roberts AB, Falk L.A. Bidirectional effects of transforming growth factor beta (TGF-beta) on colony-stimulating factor-induced human myelopoiesis in vitro:differential effects of distinct TGF-beta isoforms. Blood 78:2239-2247 (1991).
150. Piacibello W, Ferrero D, Sanavio F, Badoni R, Stacchini A, Severino A, Aglietta M. Responsiveness of highly enriched CFU-GM subpopulations from bone marrow, peripheral blood, and cord blood to hemopoietic growth inhibitors. Exp Hematol 19:1084-1089 (1991).
151. Ruscetti FW, Dubois C, Falk LA, Jacobsen SE, Sing G, Longo DL, Wiltrout RH, Keller JR. In vivo and in vitro effects of TGF-beta 1 on normal and neoplastic haemopoiesis. Ciba Found Symp 157:212-227 (1991).
152. + hematopoietic progenitor cells. Blood 79:2628-2635 (1992).
153. Broxmeyer HE, Lu L, Platzer E, Juliano L, Rubin BY. Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells. J Immunol 131:1300-1305 (1983).
154. Cashman JD, Eaves AC, Raines EW, Ross R, Eaves CJ. Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. I:Stimulatory role of a variety of mesenchymal cell activators and inhibitory role of TGF-beta. Blood 75:96-101 (1990).
155. Strife A, Lambek C, Perez A, Darzynkiewicz Z, Skierski J, Gulati S, Haley JD, ten Dijke P, Iwata KK, Clarkson BD. The effects of transforming growth factor beta 3 on the growth of highly enriched hematopoietic progenitor cells derived from normal human bone marrow and peripheral blood. Cancer Res 51:4828-4836 (1991).
156. Bursuker I, Neddermann KM, Petty BA, Schacter B, Spitalny GL, Tepper MA, Pasternak RD. In vivo regulation of nemopoiesis by transforming growth factor beta 1:stimulation of GM-CSF- and M-CSF-depcndent murine bone marrow precursors. Exp Hematol 20:431-435 (1992).
157. Hargis JB, La Russa VF, Redmond J, Kessler SW, Wright DG. Agranulocytosis associated with Mexican aspirin (dipyrone):evidence for an autoimmune mechanism affecting multipotential hematopoietic progenitors. Am J Hematol 31:213-215 (1989).
158. Hauser SP, Udupa KB, Lipschitz DA. Effects of ceftazidime, a betalactam antibiotic, on murine haemopoiesis in vitro. Br J Haematol 86:733-739 (1994).
159. Stojanovic N, Ruvidic R, Jovcic G, Mijovic A. Drug-induced agranulocytosis:bone marrow granulocytic progenitor cells. Biomed Pharmacother 44:181-184 (1990).
160. Parmentier C, Tchernia G, Subtil E, Diakhate L, Morardet N. In vitro medullary granulocytic progenitor (CFUc) cultures from 6 cases of granulocytopenias. Scand J Haematol 21:19-23 (1978).
161. Pisciotta AV, Konings SA, Ciesemier LL, Cronkite CE, Lieberman JA. Cytotoxic activity in serum of patients with clozapine-induced agranulocytosis. J Lab Clin Med 119:254-266 (1992).
162. Pisciotta AV, Konings SA, Ciesemier LL, Cronkite CE, Lieberman JA. On the possible mechanisms and predictability of clozapine-induced agranulocytosis. Drug Saf 7(Suppl I):33-44 (1992).
163. Levitt LJ. Chlorpropamide-induced pure white cell aplasia. Blood 69:394-400 (1987).
164. Parent-Massin DM, Sensebe L, Leglise MC, Guern G, Berthou C, Riche C, Abgrall JF. Relevance of in vitro studies of drug-induced agranulocytosis. Report of 14 cases. Drug Saf 9:463-469 (1993).
165. Gerson SL, Arce C, Meltzer HY. N-desmethylclozapine:a clozapine metabolite that suppresses haemopoiesis. Br J Haematol 86:555-561 (1994).
166. Aymard JP, Rouveix B, Ferry R, Janot C, May T, Legras B, Streiff F. Amodiaquine-induced agranulocyrosis:report of a case with in vitro studies of granulocyte-macrophage progenitor cells. Acta Haematol 82:40-42 (1989).
167. Aymard JP, Wioland C, Ferry R, Netter P, Streiff F. The in vitro effect of amodiaquine on bone marrow granulocyte-macrophage progenitor cells from normal subjects. Fundam Clin Pharmacol 6:1-4 (1992).
168. Ono K, Kurohara K, Yoshihara M, Shimamoto Y, Yamaguchi M. Agranulocytosis caused by ticlopidine and its mechanism. Am J Hematol 37:239-242 (1991).
169. Humphrey CA, French A, Morris TC. Prospective in vitro testing for drug-induced neutropenia in a patient requiring anti-malarial prophylaxis:confirmation of findings on exposure of patient to drug. Clin Lab Haematol 12:31-36 (1990).
170. Schreml W, Lohrmann HP. No effects of levamisole on cytotoxic drug-induced changes of human granulopoiesis. Blut 38:331-336 (1979).
171. Sperner-Unterweger B, Gaggl S, Fleischhacker WW, Barnas C, Herold M, Geissler D. Effects of clozapine on hematopoiesis and the cytokine system. Biol Psychiatry 34:536-543 (1993).
172. Fibbe WE, Claas FH, Van der Star-Dijkstra W, Schaafsma MR, Meyboom RH, Falkenburg JH. Agranulocytosis induced by propylthiouracil:evidence of a drug dependent antibody reacting with granulocytes, monocytes and haematopoietic progenitor cells. Br J Haematol 64:363-373 (1986).
173. Bloom JC, Thiem PA, Sellers TS, Deldar A, Lewis HB. Cephalosporin-induced immune cytopenia in the dog:demonstration of erythrocyte-, neutropnil-, and platelet-associated IgG following treatment with cefazedone. Am J Hematol 28:71-78 (1988).
174. Kobashi H, Adachi T, Tsubota T, Asano K, Fukai M, Namba J, Izumi K, Hoshijima T, Miura H, Sezaki T. The role of drugs and lymphocytes in granulocyte-macrophage colony formation in patients with drug induced agranulocytosis [in Japanese]. Rinsho Ketsueki 30:282-288 (1989).
175. Matsuzaki M, Tokioka T, Suga K, Sueoka E, Ono K, Sano M, Shimamoto Y, Yamaguchi M. Phenytoin induced agranulocytosis:direct and T cell-mediated mechanisms [in Japanese]. Rinsho Ketsueki 31:474-478 (1990).
176. Douer D, Eisenstein Z. Methimazole-induced agranulocytosis:growth inhibition of myeloid progenitor cells by the patient's serum. Eur J Haematol 40:91-94 (1988).
177. Pessina A, Neri MG, Muschiato A, Mineo E, Cocuzza G. Effect of fluoroquinolones on the in-vitro proliferation of myeloid precursor cells. J Antimicrob Chemother 24:203-208 (1989).
178. Deldar A, House RV, Wierda D. Bone marrow colony-forming assays. Methods Immunotoxicol 1:227-250 (1995).
179. Volpe DA, Du DL, Pohl KP, Campbell JP, Murphy MJ Jr. Utility of human bone marrow obtained incidental to orthopedic surgery for hematopoietic clonal assays. Pathobiology 59:53-56 (1991).
180. Du DL, Volpe DA, Murphy MJ Jr. Microcapillary clonogenic assays for human marrow hematopoietic progenitor cells. Int J Cell Cloning 7:303-313 (1989).
181. Meijne EI, Ploemacher RE, Vos O, Huiskamp R. The effects of graced doses of 1 MeV fission neutrons or X rays on the murine hematopoietic stroma. Radiat Res 131:302-308 (1992).
182. Xu CX, Hendry JH, Testa NG. The response of stromal progenitor cells in mouse marrow to graded repeated doses of X rays or neutrons. Radiat Res 96:82-89 (1983).
183. Klein AK, Rosenblatt LS, Stitzel KA, Greenberg B, Woo L. In vitro radiation response studies on bone marrow fibroblasts (CFU-F) obtained from normal and chronically irradiated dogs. Leuk Res 8:473-481 (1984).
184. Hendry JH, Wang SB, Testa NG. Greater sparing of stromal progenitor cells than of haemopoietic stem cells in gamma-irradiated mouse marrow using low dose-rates. Biomed Pharmacother 38:356-358 (1984).
185. Zhu H, Li Y, Trush MA. Characterization of benzo[a]pyrene quinone-induced toxicity to primary cultured bone marrow stromal cells from DBA/2 mice:potential role of mitochondrial dysfunction. Toxicol Appl Pharmacol 130:108-120 (1995).
186. Abraham NG, Bucher D, Niranjan U, Brown AC, Lutton JD, Distenfeld A, Ahmed T, Levere RD. Microenvironmental toxicity of azidothymidine:partial sparing with hemin. Blood 74:139-144 (1989).
187. Ben-Ishay Z, Prindull G, Sharon S, Borenstein A. Effects of chemotherapy on bone marrow stroma in mice with acute myelogenous leukemia. Correlation with CFU-C and CFU-D. Leuk Res 9:1059-1067 (1985).
188. Gidali J, Istvan E, Feher I. Long-term perturbation of hemopoiesis after moderate damage to stem cells. Exp Hematol 13:647-651 (1985).
189. Domenech J, Gihana E, Dayan A, Truglio D, Linassier C, Desbois I, Lamagnere JP, Colombat P, Binet C. Haemopoiesis of transplanted patients with autologous marrows assessed by long-term marrow culture. Br J Haematol 88:488-496 (1994).
190. Betticher DC, Huxol H, Muller R, Speck B, Nissen C. Colony growth in cultures from bone marrow and peripheral blood after curative treatment for leukemia and severe aplastic anemia. Exp Hematol 21:1517-1521 (1993).
191. Chang J, Geary CG, Testa NG. Long-term bone marrow damage after chemotherapy for acute myeloid leukemia does not improve with time. Br J Haematol 75:68-72 (1990).
192. Radford JA, Testa NG, Crowther D. The long-term effects of MVPP chemotherapy for Hodgkin's disease on bone marrow function. Br J Cancer 62:127-132 (1990).
193. Grande T, Gaitan S, Tejero C, Bueren JA. Residual haematopoietic damage in adult and 8-day-old mice exposed to 7 Gy of X-rays. Int J Radiat Biol 63:59-67 (1993).
194. Grande T, Bueren JA. Involvement of the bone marrow stroma in the residual hematopoietic damage induced by irradiation of adult and young mice. Exp Hematol 22:1283-1287 (1994).
195. Grande T, Bueren JA. Analysis of hematopoiesis in mice irradiated with 500 mGy of X rays at different stages of development. Radiat Res 143:327-333 (1995).
196. Burke TG, Mi Z. Preferential binding of the carboxylate form of camptothecin by human serum albumin. Anal Biochem 212:285-287 (1993).
197. Burke TG, Mi Z. The structural basis of camptothecin interactions with human serum albumin:impact on drug stability. J Med Chem 37:40-46 (1994).
198. Mi Z, Burke TG. Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry 33:10325-10336 (1994).
199. Mi Z, Burke TG. Marked interspecies variations concerning the interactions of camptothecin with serum albumins:a frequency-domain fluorescence spectroscopic study. Biochemistry 33:12540-12545 (1994).
200. Burke TG, Munshi CB, Mi Z, Jiang Y. The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs [letter], J Pharm Sci 84:518-519 (1995).
201. Song D, Hsu LF, Au JL. Binding of taxol to plastic and glass containers and protein under in vitro conditions. J Pharm Sci 85:29-31 (1996).
202. Lopez RL, Peters GJ, van Loenen AC, Pizao PE, van Rijswijk REN, Wagstaff J, Pinedo HM. The effect of schedule, protein binding and growth factors on the activity of suramin. Int J Cancer 51:921-926 (1992).
203. Miller VA, Rigas JR, Tong WP, Reid JR, Pisters KMW, Grant SC, Heelan RT, Kris MG. Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non-small-cell lung cancer. Cancer Chemother Pharmacol 40:415-418 (1997).
204. Myers SR, Fiesher JW. Metabolism of the carcinogen 3-methylcholanthrene in human bone marrow preparations. Drug Metab Dispos 18:664-669 (1990).
205. Twerdok LE, Trush MA. Differences in quinone reductase activity in primary bone marrow stromal cells derived from C57BL/6 and DBA/2 mice. Res Commun Chem Pathol Pharmacol 67:375-386 (1990).
206. Thomas DJ, Sadler A, Subrahmanyam W, Siegel D, Reasor MJ, Wierda D, Ross D. Bone marrow stromal cell bioactivation and detoxification of the benzene metabolite hydroquinone:comparison of macrophages and fibroblastoid cells. Mol Pharmacol 37:255-262 (1990).
207. Twerdok LE, Trush MA. Studies on biochemical determinants of quinone-induced toxicity in primary murine bone marrow stromal cells. Adv Exp Med Biol 283:843-846 (1991).
208. Twerdok LE, Mosebrook DR, Trush MA. Comparison of oxidant-generation and BP-diol activation by bone marrow cells from C57Bl/6 and DBA/2 mice:implications for risk of bone marrow toxicity induced by polycyclic hydrocarbons. Toxicol Appl Pharmacol 112:266-272 (1992).
209. Twerdok LE, Rembish SJ, Trush MA. Induction of quinone reductase and glutathione in bone marrow cells by 1,2-dithiole-3-thione:effect on hydroquinone-induced cytotoxicity. Toxicol Appl Pharmacol 112:273-281 (1992).
210. Ganousis LG, Goon D, Zyglewska T, Wu KK, Ross D. Cell-specific metabolism in mouse bone marrow stroma:studies of activation and detoxification of benzene metabolites. Mol Pharmacol 42:1118-1125 (1992).
211. Gianni L, Vigano L, Surbone A, Ballinari D, Casali P, Tarella C, Collins JM, Bonadonna G. Pharmacology and clinical toxicity of 4′-iodo-4′-deoxydoxorubicin:an example of successful application of pharmacokinetics to dose escalation in phase I trials. J Natl Cancer Inst 82:469-477 (1990).
212. Deldar A, Stevens CE, Beineke PJ. Comparative distribution of marrow CFU-e and CFU-gm progenitors in different anatomic sites in the dog. Int J Cell Cloning 8:196-208 (1990).
213. Deldar A, Stevens CE, Rodocker KB. Canine BFU-e progenitors:adaptation of a reproducible assay and anatomical distribution. Int J Cell Cloning 9:579-593 (1991).
214. Demirer T, Rowley S, Buckner CD, Appelbaum FR, Lilleby K, Storb R, Schiffman K, Bensinger WI. Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer. J Clin Oncol 13:1714-1719 (1995).
215. + cells in apheresis products from patients mobilized for peripheral blood progenitors with different regimens. Bone Marrow Transplant 13:479-485 (1994).
216. Urashima M, Uchiyama H, Hoshi Y, Deguchi Y, Kamijou M, Katou Y, Fujisawa K, Akatsuka J, Maekawa K. Prediction of engraftment after peripheral blood stem cell transplantation by CD34-positive cells in grafts. Acta Paediatr Jpn 35:325-331 (1993).
217. Holberg-Petersen M, Rollag H, Beck S, Øverli I, Tjønnfjord G, Abrahamsen TG, Degré M, Hestdal K. Direct growth suppression of myeloid bone marrow progenitor cells but not cord blood progenitors by human cytomegalovirus in vitro. Blood 88:2510-2516 (1996).
218. Leglise MC, de Tailly PD, Vignot JL, LeBot MA, LcRoux AM, Riche C. A cellular model for drug interactions on hematopoiesis:the use of human umbilical cord blood progenitors as a model for the study of drug-related myelosuppression of normal hematopoiesis. Cell Biol Toxicol 12:39-53 (1996).
219. Erickson-Miller CL, May RD, Tomaszewski J, Osborn B, Murphy MJ, Page JG, Parchment RE. Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro. Cancer Chemother Pharmacol 39:467-472 (1997).